MYCOF - Mydecine gets Health Canada approval for psilocybin related cultivation expansion

Mydecine Innovations (MYCOF) has received approval from Health Canada to expand its cultivation capabilities at the company's Canadian Current Good Manufacturing Practice ((cGMP)) facility at Applied Pharmaceutical Innovation ((API)).Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners.The company believes that the increased cultivation will allow it to more efficiently and quickly study the medical utility of naturally occurring psilocybin and psilocybin-like compounds."It (expansion) will also enhance our ability to produce pharmaceutical grade psilocybin at scale and increase our capacity to support our novel drug candidates like MYCO-001 and study its production in nature,” Rob Roscow, Chief Science Officer at Mydecine said.

For further details see:

Mydecine gets Health Canada approval for psilocybin related cultivation expansion